CYCC Stock Overview
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases.
Cyclacel Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.77|
|52 Week High||US$4.53|
|52 Week Low||US$0.76|
|1 Month Change||-38.93%|
|3 Month Change||-54.47%|
|1 Year Change||-77.89%|
|3 Year Change||-92.73%|
|5 Year Change||-97.90%|
|Change since IPO||-99.99%|
Recent News & Updates
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash WiselyAug 17
Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear ThesisAug 07
|CYCC||US Biotechs||US Market|
Return vs Industry: CYCC underperformed the US Biotechs industry which returned -10.2% over the past year.
Return vs Market: CYCC underperformed the US Market which returned -14.8% over the past year.
|CYCC Average Weekly Movement||10.6%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: CYCC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: CYCC's weekly volatility (11%) has been stable over the past year.
About the Company
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis.
Cyclacel Pharmaceuticals, Inc. Fundamentals Summary
|CYCC fundamental statistics|
Is CYCC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CYCC income statement (TTM)|
|Cost of Revenue||US$3.03m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.54|
|Net Profit Margin||0.00%|
How did CYCC perform over the long term?See historical performance and comparison